XORTX Therapeutics Inc. (XRTX.V)
CAD 1.62
(-7.43%)
CAD 1.62
(-7.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.38 Million CAD | 40.29% |
| 2022 | -10.68 Million CAD | -158.42% |
| 2021 | -4.13 Million CAD | -218.01% |
| 2020 | -1.3 Million CAD | -129.79% |
| 2019 | -565.96 Thousand CAD | 51.09% |
| 2018 | -1.15 Million CAD | -146.51% |
| 2017 | -469.44 Thousand CAD | -15.81% |
| 2016 | -405.33 Thousand CAD | 0.0% |
| 2014 | -36.92 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 873.3 Thousand USD | 118.92% |
| 2024 Q2 | -3.12 Million USD | -457.43% |
| 2023 Q2 | -1.75 Million USD | 8.22% |
| 2023 FY | -8.16 Million CAD | 23.65% |
| 2023 Q3 | -1.38 Million USD | 20.96% |
| 2023 Q4 | -4.61 Million USD | -232.23% |
| 2023 Q1 | -1.91 Million USD | -20.12% |
| 2022 Q2 | -5.17 Million CAD | -34.15% |
| 2022 Q1 | -3.85 Million CAD | -22.55% |
| 2022 Q4 | -1.59 Million CAD | 58.91% |
| 2022 Q3 | -3.88 Million CAD | 24.97% |
| 2022 FY | -10.68 Million CAD | -158.42% |
| 2021 FY | -4.13 Million CAD | -218.01% |
| 2021 Q4 | -3.14 Million CAD | -677.2% |
| 2021 Q2 | -865.44 Thousand CAD | -1.08% |
| 2021 Q1 | -856.18 Thousand CAD | -125.11% |
| 2021 Q3 | -404.87 Thousand CAD | 53.22% |
| 2020 Q4 | -380.34 Thousand CAD | 0.39% |
| 2020 Q2 | -370.89 Thousand CAD | -121.53% |
| 2020 Q1 | -167.42 Thousand CAD | -1.54% |
| 2020 FY | -1.3 Million CAD | -129.79% |
| 2020 Q3 | -381.84 Thousand CAD | -2.95% |
| 2019 Q1 | -127.65 Thousand CAD | -105.16% |
| 2019 FY | -565.96 Thousand CAD | 51.09% |
| 2019 Q2 | -140.25 Thousand CAD | -9.87% |
| 2019 Q4 | -164.88 Thousand CAD | -23.81% |
| 2019 Q3 | -133.17 Thousand CAD | 5.04% |
| 2018 Q1 | -3.05 Million CAD | -1142.43% |
| 2018 Q4 | 2.47 Million CAD | 940.16% |
| 2018 Q2 | -277.44 Thousand CAD | 90.93% |
| 2018 Q3 | -294.37 Thousand CAD | -6.1% |
| 2018 FY | -1.15 Million CAD | -146.51% |
| 2017 Q1 | -67.15 Thousand CAD | -16.84% |
| 2017 FY | -469.44 Thousand CAD | -15.81% |
| 2017 Q4 | -246.18 Thousand CAD | -173.97% |
| 2017 Q3 | -89.85 Thousand CAD | -89.25% |
| 2017 Q2 | -47.48 Thousand CAD | 29.3% |
| 2016 FY | -405.33 Thousand CAD | 0.0% |
| 2016 Q4 | -57.47 Thousand CAD | -10.37% |
| 2016 Q3 | -52.07 Thousand CAD | -17.8% |
| 2016 Q2 | -44.2 Thousand CAD | -425.13% |
| 2016 Q1 | 13.59 Thousand CAD | 112.47% |
| 2015 Q1 | -17.39 Thousand CAD | -171.9% |
| 2015 Q2 | -62.62 Thousand CAD | -259.93% |
| 2015 Q4 | -109.05 Thousand CAD | -134.24% |
| 2015 Q3 | -46.55 Thousand CAD | 25.66% |
| 2014 Q3 | -6678.00 CAD | -3.6% |
| 2014 FY | -36.92 Thousand CAD | 0.0% |
| 2014 Q2 | -6446.00 CAD | 0.0% |
| 2014 Q4 | -6399.00 CAD | 4.18% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.35 Million CAD | -90.211% |
| Covalon Technologies Ltd. | -4.48 Million CAD | -42.163% |
| Hemostemix Inc. | -2.33 Million CAD | -173.485% |
| Universal Ibogaine Inc. | 497.15 Thousand CAD | 1383.689% |
| Kane Biotech Inc. | -3.35 Million CAD | -90.085% |
| MedMira Inc. | -1.94 Million CAD | -228.232% |
| Marvel Biosciences Corp. | -2.31 Million CAD | -175.207% |
| NervGen Pharma Corp. | -17.77 Million CAD | 64.1% |